Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia.

Dior M, Coriat R, Mir O, Brezault C, Perkins G, Dhooge M, Goldwasser F, Chaussade S.

Am J Med. 2012 Aug;125(8):828-30. doi: 10.1016/j.amjmed.2012.04.026.

PMID:
22840668
2.

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS.

Med Oncol. 2009;26(1):32-7. doi: 10.1007/s12032-008-9077-8. Epub 2008 May 22.

PMID:
18498064
3.

Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.

Tezuka T, Hamada C, Ishida H, Ooshiro M, Matsuoka H, Kawasaki S, Mishima H, Maeda K, Sakamoto J, Koda K.

Invest New Drugs. 2013 Oct;31(5):1321-9. doi: 10.1007/s10637-013-9982-3. Epub 2013 Jul 2.

4.

Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.

Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, Pericay C, Pastorelli D, Tarazi J, Rosbrook B, Bloom J, Ricart AD, Kim S, Sobrero AF.

Clin Colorectal Cancer. 2013 Dec;12(4):239-47. doi: 10.1016/j.clcc.2013.09.001.

PMID:
24188685
5.

[Idiopathic thrombocytopenic purpura during chemotherapy for liver metastasis of rectal cancer].

Murata K, Mikami K, Yamada M, Ide Y, Owada Y, Nishigaki T, Nagase H, Mukai R, Momozane T, Murakami M, Okada K, Yanagisawa T, Ebisui C, Yokouchi H, Kinuta M.

Gan To Kagaku Ryoho. 2010 Nov;37(12):2605-7. Japanese.

PMID:
21224653
6.

A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.

Nakayama N, Sato A, Tanaka S, Shimada K, Konishi K, Sasaki E, Hibi K, Ichikawa H, Kikuchi Y, Sakuyama T, Sekikawa T, Hayashi K, Nishina H; Tokyo Cooperative Oncology Group, Tokyo, Japan.

Invest New Drugs. 2015 Aug;33(4):954-62. doi: 10.1007/s10637-015-0239-1. Epub 2015 May 5.

PMID:
25937430
7.

Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.

Duffy A, Shia J, Huitzil-Melendez FD, Fong Y, O'Reilly EM.

Clin Colorectal Cancer. 2008 Mar;7(2):140-3. doi: 10.3816/CCC.2008.n.019.

PMID:
18501074
8.

[Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].

Guo X, Liu TS, Yu YY, Zhou YH, Chen Y, Zhuang RY, Cui YH.

Zhonghua Zhong Liu Za Zhi. 2013 Aug;35(8):604-7. Chinese.

PMID:
24314219
9.

[Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].

Mansueto G, Longo F.

Tumori. 2008 Jul-Aug;94(4):suppl 1-14. Review. Italian. No abstract available.

PMID:
18822711
10.

Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.

Dipetrillo T, Pricolo V, Lagares-Garcia J, Vrees M, Klipfel A, Cataldo T, Sikov W, McNulty B, Shipley J, Anderson E, Khurshid H, Oconnor B, Oldenburg NB, Radie-Keane K, Husain S, Safran H.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):124-9. doi: 10.1016/j.ijrobp.2010.08.005. Epub 2010 Oct 13.

PMID:
20947267
11.

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.

Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL.

Ann Oncol. 2010 Feb;21(2):297-304. doi: 10.1093/annonc/mdp489. Epub 2009 Nov 25.

PMID:
19940012
12.

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd; Eastern Cooperative Oncology Group Study E3200.

J Clin Oncol. 2007 Apr 20;25(12):1539-44.

PMID:
17442997
13.

Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.

Vaidyanathan G, Groman A, Wilding G, Fakih MG.

Oncology. 2010;79(1-2):67-71. doi: 10.1159/000319549. Epub 2010 Nov 12.

PMID:
21071992
14.

Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.

Usui K, Katou Y, Furushima K, Tanaka Y, Tanai C, Ishihara T.

Jpn J Clin Oncol. 2011 Apr;41(4):498-502. doi: 10.1093/jjco/hyr006. Epub 2011 Feb 7.

PMID:
21303791
15.

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A.

N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.

16.

A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.

Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R.

Cancer. 2010 Sep 1;116(17):4086-94. doi: 10.1002/cncr.25277.

17.

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.

Kochi M, Akiyama Y, Aoki T, Hagiwara K, Takahashi T, Hironaka K, Teranishi F, Osuka F, Takeuchi M, Fujii M, Nakajima T.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1097-102. doi: 10.1007/s00280-013-2292-9. Epub 2013 Sep 22.

PMID:
24057041
18.

Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.

Walter H, Thomas AL.

Br J Cancer. 2013 Jun 25;108(12):2417-8. doi: 10.1038/bjc.2013.244. No abstract available.

19.

Perforating dermatosis in a patient receiving bevacizumab.

Vano-Galvan S, Moreno C, Medina J, Pérez-García B, García-López JL, Jaén P.

J Eur Acad Dermatol Venereol. 2009 Aug;23(8):972-4. doi: 10.1111/j.1468-3083.2008.03078.x. Epub 2009 Mar 17. No abstract available.

PMID:
19470057
20.

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY.

J Clin Oncol. 2014 Jul 20;32(21):2240-7. doi: 10.1200/JCO.2013.53.2473. Epub 2014 Mar 31.

PMID:
24687833

Supplemental Content

Support Center